Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

664 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune checkpoint inhibitors in NSCLC.
Johnson DB, Rioth MJ, Horn L. Johnson DB, et al. Curr Treat Options Oncol. 2014 Dec;15(4):658-69. doi: 10.1007/s11864-014-0305-5. Curr Treat Options Oncol. 2014. PMID: 25096781 Free PMC article. Review.
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM. Johnson DB, et al. Among authors: johnson as. Nat Commun. 2016 Jan 29;7:10582. doi: 10.1038/ncomms10582. Nat Commun. 2016. PMID: 26822383 Free PMC article.
Emerging targeted therapies for melanoma.
Johnson DB, Pollack MH, Sosman JA. Johnson DB, et al. Expert Opin Emerg Drugs. 2016 Jun;21(2):195-207. doi: 10.1080/14728214.2016.1184644. Epub 2016 May 17. Expert Opin Emerg Drugs. 2016. PMID: 27148822 Review.
PD-1/PD-L1 blockade in renal cell cancer.
Beckermann KE, Johnson DB, Sosman JA. Beckermann KE, et al. Among authors: johnson db. Expert Rev Clin Immunol. 2017 Jan;13(1):77-84. doi: 10.1080/1744666X.2016.1214575. Epub 2016 Jul 28. Expert Rev Clin Immunol. 2017. PMID: 27426025 Free PMC article. Review.
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
Betof AS, Nipp RD, Giobbie-Hurder A, Johnpulle RAN, Rubin K, Rubinstein SM, Flaherty KT, Lawrence DP, Johnson DB, Sullivan RJ. Betof AS, et al. Among authors: johnson db. Oncologist. 2017 Aug;22(8):963-971. doi: 10.1634/theoncologist.2016-0450. Epub 2017 May 5. Oncologist. 2017. PMID: 28476944 Free PMC article.
Emerging biomarkers for cancer immunotherapy in melanoma.
Axelrod ML, Johnson DB, Balko JM. Axelrod ML, et al. Among authors: johnson db. Semin Cancer Biol. 2018 Oct;52(Pt 2):207-215. doi: 10.1016/j.semcancer.2017.09.004. Epub 2017 Sep 14. Semin Cancer Biol. 2018. PMID: 28917578 Free PMC article. Review.
MDM2 Antagonists Counteract Drug-Induced DNA Damage.
Vilgelm AE, Cobb P, Malikayil K, Flaherty D, Andrew Johnson C, Raman D, Saleh N, Higgins B, Vara BA, Johnston JN, Johnson DB, Kelley MC, Chen SC, Ayers GD, Richmond A. Vilgelm AE, et al. Among authors: johnson db. EBioMedicine. 2017 Oct;24:43-55. doi: 10.1016/j.ebiom.2017.09.016. Epub 2017 Sep 19. EBioMedicine. 2017. PMID: 29030058 Free PMC article.
Biomarkers for immune therapy in melanoma.
Johnson DB, Chon J, Johnson MR, Balko JM. Johnson DB, et al. Among authors: johnson mr. Semin Cutan Med Surg. 2018 Jun;37(2):120-126. doi: 10.12788/j.sder.2018.019. Semin Cutan Med Surg. 2018. PMID: 30040089 Free PMC article. Review.
664 results